DBV Technologies (DBVT) Share-based Compensation (2020 - 2026)
DBV Technologies (DBVT) reported Share-based Compensation of $2.3 million for Q1 2026, up 35.29% year-over-year from $1.7 million in Q1 2025, and up 19.54% on a QoQ basis from $1.9 million in Q4 2025.
DBV Technologies (DBVT) has 7 years of Share-based Compensation data on file, last reported at $2.3 million in Q1 2026.
- Quarterly Share-based Compensation rose 35.29% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.0 million (up 37.25% YoY) and the FY2025 annual result came in at $5.4 million, up 16.6% from the prior year.
- Share-based Compensation advanced to $2.3 million in Q1 2026 per DBVT's latest filing, from $1.9 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $2.3 million in Q1 2026 and bottomed at -$453000.0 in Q4 2024.
- The 5-year median for Share-based Compensation is $1.5 million (2024), against an average of $1.4 million.
- The widest annual swing landed in 2024, when Share-based Compensation tumbled 137.16%; it then jumped 524.72% in 2025.
- Tracing DBVT's Share-based Compensation over 5 years: stood at $1.6 million in 2022, then declined by 24.29% to $1.2 million in 2023, then slumped by 137.16% to -$453000.0 in 2024, then jumped by 524.72% to $1.9 million in 2025, then grew by 19.54% to $2.3 million in 2026.
- Per Business Quant, the three latest DBVT Share-based Compensation figures stand at $2.3 million (Q1 2026), $1.9 million (Q4 2025), and $516000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | DBV Technologies | 8.00 Bn | 7.77 Bn | -3.90 Mn | 2.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.30 Mn |
| Mar 31, 2026 | 2.30 Mn |
| Dec 31, 2025 | 1.92 Mn |
| Dec 31, 2025 | 1.92 Mn |
| Sep 30, 2025 | 516,000.00 |
| Sep 30, 2025 | 516,000.00 |
| Jun 30, 2025 | 1.25 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Mar 31, 2025 | 1.70 Mn |
| Mar 31, 2025 | 1.70 Mn |
| Dec 31, 2024 | -453,000.00 |
| Dec 31, 2024 | -453,000.00 |
| Sep 30, 2024 | 1.59 Mn |
| Sep 30, 2024 | 1.59 Mn |
| Jun 30, 2024 | 1.53 Mn |
| Jun 30, 2024 | 1.53 Mn |
| Mar 31, 2024 | 1.96 Mn |
| Mar 31, 2024 | 1.96 Mn |
| Dec 31, 2023 | 1.22 Mn |
| Dec 31, 2023 | 1.22 Mn |
| Sep 30, 2023 | 1.35 Mn |
| Sep 30, 2023 | 1.35 Mn |
| Jun 30, 2023 | 1.81 Mn |
| Jun 30, 2023 | 1.81 Mn |
| Mar 31, 2023 | 1.63 Mn |
| Mar 31, 2023 | 1.63 Mn |
| Dec 31, 2022 | 1.61 Mn |
| Dec 31, 2022 | 1.61 Mn |
| Sep 30, 2022 | 975,000.00 |
| Sep 30, 2022 | 975,000.00 |
| Jun 30, 2022 | 1.08 Mn |
| Jun 30, 2022 | 1.08 Mn |
| Mar 31, 2022 | 1.36 Mn |
| Mar 31, 2022 | 1.36 Mn |
| Dec 31, 2021 | -956,000.00 |
| Dec 31, 2021 | -956,000.00 |
| Sep 30, 2021 | 1.55 Mn |
| Sep 30, 2021 | 1.55 Mn |
| Jun 30, 2021 | 1.09 Mn |
| Jun 30, 2021 | 1.09 Mn |
| Mar 31, 2021 | 1.43 Mn |
| Mar 31, 2021 | 1.43 Mn |
| Dec 31, 2020 | 1.84 Mn |
| Dec 31, 2020 | 1.84 Mn |
| Sep 30, 2020 | -74,000.00 |
| Sep 30, 2020 | -74,000.00 |
| Jun 30, 2020 | -5.96 Mn |
| Jun 30, 2020 | -5.96 Mn |
| Mar 31, 2020 | 3.07 Mn |
| Mar 31, 2020 | 3.07 Mn |